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Abstract
Granulocyte colony-stimulating factor (G-CSF) mediates the proliferation, differentiation and activation of cells in the
granulocytic lineage. However, knowledge about the specific signaling pathways utilized by the G-CSF receptor (G-CSF-R)
upon ligand binding remains limited. In this report, we show rapid phosphorylation of Shc upon stimulation of NFS-60 cells
with G-CSF, and inducible association of Shc and Grb2 with the G-CSF-R in these cells. Using a tyrosine-phosphorylated
GST^G-CSF-R fusion we demonstrate that Shc, Grb2 and SHP-2 directly bind the receptor via their respective SH2
domains, suggesting multiple routes of MAPK activation from the G-CSF-R are possible. In addition, we have identified an
unknown p40 molecule which is associated with the G-CSF-R transiently following G-CSF stimulation, and a constitutively-
associated p37 molecule. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Granulocyte colony-stimulating factor (G-CSF)
stimulates the proliferation, di¡erentiation and func-
tional activation of cells of the granulocyte lineage
[1]. G-CSF also causes the mobilization of early pre-
cursor cells from the marrow [2], which has lead to
its widespread clinical application in the reconstitu-
tion of hematopoietic cells in patients following bone
marrow transplantation and chemotherapy [3]. The
G-CSF receptor, G-CSF-R, is a homo-oligomer of a
single-chain molecule, which resembles the common
L subunit of the IL-3, GM-CSF and IL-5 receptors
[4], all of which are members of the cytokine receptor
family [5]. Like other family members, the G-CSF-R
lacks an intrinsic tyrosine kinase activity, yet tyrosine
phosphorylation of numerous proteins following lig-
and binding has been reported, including p80cÿRel
[6], p55Lyn and p72Syk [7], and JAKs 1 and 2 [8].
Receptor phosphorylation is believed to be carried
out by one or more kinases, such as the JAK kinases,
JAK1, JAK2 or Tyk2 [8^12], or the Src kinase,
p55Lyn [7]. Downstream pathways include p21ras,
Raf-1, and MAPK [10,13^15], and the transcription
factors p80cÿRel [6], and STATs 1, 3 and 5A [9,12,14],
with some of these pathways requiring particular re-
gions of the receptor [14,16]. However, the under-
standing of G-CSF signal transduction lags signi¢-
cantly behind that of other receptor systems.
The Shc proteins have been shown to interact with
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various growth factor receptors, including the EGF
receptor, and non-receptor tyrosine kinases, such as
v-Src [17,18]. Receptor activation has been shown to
lead to tyrosine phosphorylation of Shc, and inter-
action with a Grb2/Sos complex to activate p21ras
and ultimately MAPK [19,20]. In addition, the tyro-
sine phosphatase SHP-2 can associate with Grb2 to
simulate the Ras/MAPK pathway [21^23]. Since we
and others have observed G-CSF-mediated activa-
tion of p21ras, Raf-1 and MAPK [10,13^15], we set
out to analyze the involvement of Shc, Grb2 and
SHP-2 in signaling from the murine G-CSF-R. Our
studies showed association of Shc, Grb2 and SHP-2
to the tyrosine-phosphorylated G-CSF-R cytoplas-
mic domain, via direct binding through their respec-
tive SH2 domains, suggesting multiple routes of
MAPK activation are possible. In addition, we
sought to examine whether other cellular proteins
might interact with the G-CSF-R. This revealed in-
ducible binding of a p40 molecule, and constitutive
association of a p37 molecule with the cytoplasmic
domain of the G-CSF-R.
2. Materials and methods
2.1. Cells and culture conditions
NFS-60 cells are a myeloid-derived, G-CSF/IL-
3-dependent cell line [24] obtained from Dr. J. Ihle
(St. Jude’s Hospital, Memphis, TN). Unless other-
wise speci¢ed, these were grown in DMEM contain-
ing 2 mM glutamine, 10% (v/v) FBS and 10 ng/ml
recombinant human G-CSF (Amgen, Melbourne,
Australia) at 37‡C in 5% CO2, as described [25]. Cells
were subsequently washed in DMEM and then incu-
bated in DMEM +10% FBS without growth factor
for 14 h before use to render them quiescent. For 35S
labelling experiments, cells were rendered quiescent
as described above for 12 h, then incubated for a
further 2 h in methionine- and serum-free media sup-
plemented with 1 mCi Tran35-label (ICN-Flow, Syd-
ney, Australia) per 107 cells, before stimulation.
2.2. Immunoprecipitation and Western blot analysis
Quiescent and growth-factor-treated cells were
lysed in lysis bu¡er (10 mM Tris^HCl pH 7.2, con-
taining 1% (v/v) NP-40, 0.5% deoxycholate, 70 IU/ml
aprotinin, 0.1 mM Pefabloc, 10Wg/ml leupeptin,
100 mM NaF, 1 mM EDTA and 200 WM orthova-
nadate) and clari¢ed by centrifugation at 12 000Ug
for 15 min. Lysates (50 Wg) were incubated with 2 Wg
of glutathione Sepharose-immobilized fusion protein,
or 1 Wg of rabbit polyclonal anti-Grb2, anti-Shc (Up-
state Biotechnology, Lake Placid, NY) or anti-G-
CSF-R (this study), overnight at 4‡C. For immuno-
precipitations, the immune complexes were collected
by incubation with Protein A-Sepharose 4B (Phar-
macia, Uppsala, Sweden) for a further 30 min. The
precipitates were washed three times in lysis bu¡er,
electrophoresed on 10% SDS-PAGE gels, and trans-
ferred to Hybond-C membranes. Membranes were
blocked in 3% (w/v) BSA, 1% (w/v) ovalbumin in
PBS (BOP bu¡er), and incubated with rabbit poly-
clonal anti-Shc, anti-G-CSF-R, or monoclonal anti-
phosphotyrosine 4G10 (Upstate) in BOP bu¡er for
2 h at room temperature. Membranes were washed
extensively in TBS plus 0.1% Tween 20, and bound
antibodies visualized with HRP-conjugated swine
anti-rabbit, or rabbit anti-mouse Ig (Dako, La Jolla,
CA), using the ECL system (Amersham) and follow-
ing the manufacturer’s instructions.
2.3. Plasmids, fusion proteins, and antibodies
A DNA fragment corresponding to the region
coding for the cytoplasmic domain of the murine
G-CSF receptor (aa 632^812) was cloned into
pGEX2TK (Pharmacia), to generate a plasmid des-
ignated p2TK-GR. For antibody production, this
plasmid was transformed into XL-1 Blue (Strata-
gene, La Jolla, CA). Exponentially growing cultures
were induced with 0.1 mM IPTG (isopropyl L-D-
thiogalactopyranoside) for 4 h at 37‡C. The cells
were then washed in TBS and lysed by sonication
in TEND (TBS, 1 mM EDTA, 1 mM DTT, 0.5%
NP-40). The lysate was centrifuged at 12 000Ug for
20 min and incubated with glutathione Sepharose 4B
beads (AMRAD, Melbourne, Australia) for 30 min.
The beads were washed extensively with TEND, be-
fore elution of the puri¢ed fusion protein (GST^G-
CSF-R) with 25 mM Glutathione in TE. This was
used to immunize New Zealand White rabbits ac-
cording to standard protocols. The resultant antisera
was shown to be speci¢c due to its ability to recog-
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nize the three forms of the murine G-CSF-R ex-
pressed in NFS-60 cells [26] or FDCP-1 cells trans-
fected with the murine G-CSF-R, with no signal ob-
served in parental FDCP-1 cells (A.C. Ward and
X.F. Csar, unpublished). For the production of ty-
rosine-phosphorylated G-CSF-R cytoplasmic do-
main, plasmid p2TK-GR was introduced into the
Escherichia coli strain TKX1 (Stratagene, La Jolla,
CA), which contains an inducible tyrosine kinase.
Fusion protein was produced as described above,
except a second induction was carried out in TK
induction media for 2 h at 30‡C, according to the
manufacturer’s instructions. The puri¢ed protein was
32P-labelled with heart muscle kinase and cleaved
with thrombin to remove the GST tag, as described
previously [27,28]. In addition, the C-terminus of
SHP-2 (aa 526^593) was cloned into pET-15b (No-
vagen, Madison, WI, USA) and introduced into the
E. coli strain TKB1 (Stratagene). Expression of tyro-
sine phosphorylated SHP-2 C-terminus was achieved
as described above, with the protein puri¢ed on Ni-
NTA-Agarose resin (Qiagen, Hilden, Germany) ac-
cording to the manufacturer’s instructions, and la-
beled as above.
2.4. Far Western blot analysis
GST fusions of the following SH2 domain con-
taining molecules were puri¢ed as described above:
Grb2 (SH3^SH2^SH3, aa 1^217), Grb2(m) (SH3^
SH2mutant^SH3, aa 1^217), Shc (SH2, aa 366^
473), CrkL (SH2, aa 10^104), Grb14 (SH2, aa 426^
540), Src (SH2, aa 145^248), and SHP-2(n+c) (SH2-
SH2, aa 1^215). These were then electrophoresed on
10% SDS-PAGE gels [29], and electrophoretically
transferred to Hybond-C membranes (Amersham,
Sydney, Australia). The ¢lters were then processed
through a denaturation^renaturation cycle [30] and
probed with 32P-labelled, tyrosine-phosphorylated G-
CSF-R cytoplasmic domain or SHP-2 C-terminus, as
described [28].
3. Results and discussion
Shc is an SH2-containing signaling protein with no
apparent catalytic function, which is tyrosine-phos-
phorylated following activation of a diverse range of
receptors. Phosphorylated Shc can then bind Grb2/
Sos complexes to activate p21ras, Raf-1 and the
MAPK pathway [20]. In addition, Grb2 can lead to
activation of the Ras/MAPK pathway via associa-
tion with SHP-2 [21^23]. We and others have ob-
served G-CSF-mediated activation of p21ras, Raf-1
and the ERK1 and ERK2 isoforms of MAPK
[10,13^15]. Therefore, we sought to investigate a pos-
sible role for Shc and Grb2 in G-CSF signaling. We
¢rst immunoprecipitated Shc from NFS-60 lysates
following G-CSF stimulation (Fig. 1). Western blot
analysis with anti-phosphotyrosine 4G-10 antibodies
indicated tyrosine-phosphorylation of the p52 iso-
form of Shc in response to G-CSF. Importantly,
analysis with anti-G-CSF-R antiserum showed, in
addition, the inducible association of Shc with the
G-CSF-R. The two bands represent di¡erent glyco-
sylated isoforms of the G-CSF-R previously reported
in these cells [26]. Re-probing with anti-Shc antise-
rum con¢rmed equal loading of Shc in these experi-
ments. Immunoprecipitation with Grb2, and Western
blot analysis with anti-G-CSF-R antiserum, showed
similar inducible association of Grb2 with the G-
CSF-R (Fig. 2). Re-probing with anti-Grb2 con-
¢rmed equal loading (data not shown).
Since the kinetics of Shc and Grb2 association
were similar to those for G-CSF-R tyrosine phos-
Fig. 1. Phosphorylation and co-immunoprecipitation of Shc
with the G-CSF-R. Lysates prepared from quiescent and stimu-
lated NFS-60 cells were immunoprecipitated with anti-Shc, and
subjected to Western blot analysis with the antibodies indicated,
as described in Section 2. This is a representative of several in-
dependent experiments.
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phorylation in these cells (A.C. Ward and X.F. Csar,
unpublished), we analyzed whether their association
with the receptor was direct and dependent on tyro-
sine phosphorylation. To achieve this we produced a
GST-fusion with the cytoplasmic domain of the mur-
ine G-CSF-R in a tyrosine-phosphorylated form.
Multiple species were observed which were reactive
with anti-phosphotyrosine 4G-10 antibodies, indicat-
ing the protein was phosphorylated at multiple sites
(data not shown). The tyrosine phosphorylated
GST^G-CSF-R was 32P-labelled using heart muscle
kinase, cleaved with thrombin to remove the GST,
and used in an in vitro binding assay on various
GST^SH2 domain fusions, which had been immobi-
lized on nitrocellulose. The receptor was found to
bind speci¢cally to GST^Shc(SH2) and GST^
Grb2(SH3^SH2^SH3), but not to a GST^Grb2
which contains a mutant SH2 domain, or to fusions
of GST with the SH2 domains of CrkL, v-Src, or
Grb14 (Fig. 3). This binding was not competed out
by a forty-fold excess of unlabelled non-tyrosine
phosphorylated receptor (data not shown). There-
fore, it appears that both Shc and Grb2 can bind
directly to the activated G-CSF-R via their respective
SH2 domains, implicating these molecules in G-CSF
signal transduction. Interestingly, these molecules
may compete for the same phosphorylated tyrosine
residue of the receptor, Y763 (Table 1), since its se-
quence context matches the consensus binding site
for the SH2 domains of both Shc (pY-I/E/Y-X-I/L/
M) and Grb2 (pY-bulky amino acid-N) [31].
Since Grb2/SHP-2 complexes have been reported
in response to G-CSF stimulation [16], we also ex-
amined whether SHP-2 might also interact directly
with the G-CSF-R. Far Western analysis showed
speci¢c interaction between SHP-2 SH2 domains
and tyrosine-phosphorylated G-CSF-R cytoplasmic
domain (Fig. 4). This possibly occurs at multiple
sites, since each of the cytoplasmic tyrosines of the
murine G-CSF-R (Table 1) shows some homology to
the consensus SHP-2 SH2 binding site (Y^I/V^X^V/
I/L/P) [32]. Other studies have shown that Grb2/
SHP-2 complexes are the result of interaction of
the Grb2 SH2 domain with phosphorylated tyrosines
in the SHP-2 C-terminus [33]. We used Far Western
analysis to con¢rm that, from a range of signaling
molecules, only Grb2 interacted with tyrosine-phos-
Fig. 3. Direct association of Shc and Grb2 with recombinant
tyrosine-phosphorylated G-CSF-R. GST-fusions of various SH2
domain-containing signaling molecules were separated on dupli-
cate SDS-PAGE gels and either stained with Coomassie (A) or
transferred to nitrocellulose for far Western analysis (B) with
32P-labeled, tyrosine-phosphorylated G-CSF-R as a probe. This
result was con¢rmed in several independent experiments.
Table 1







Fig. 2. Co-immunoprecipitation of Grb2 with the G-CSF-R.
Lysates prepared from quiescent and stimulated NFS-60 cells
were immunoprecipitated with anti-Grb2, and subjected to
Western blot analysis with anti-G-CSF-R antisera, as described
in Section 2. This is a representative of several independent ex-
periments.
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phorylated SHP-2 C-terminus (Fig. 4), which con-
tains two sites, pY542-T-N and pY580-E-N, that also
match the Grb2 SH2 consensus. Thus, it appears
that SHP-2 can dock to the G-CSF-R via its SH2
domains, and thereby generate additional Grb2
docking site(s) in the G-CSF-R complex.
The direct binding and tyrosine-phosphorylation
of Shc proteins we have shown in NFS-60 cells sug-
gests a classical Shc/Grb2/Sos/Ras route of MAPK
activation occurs in response to G-CSF. This is sup-
ported by our previous studies showing activation of
Ras, Raf-1 and ERK in these cells, with kinetics
consistent with that of Shc activation shown here
[15], as well as data from Ba/F3 cells showing G-
CSF activation of Shc/Grb2 complexes [16], presum-
ably by binding of the Grb2 SH2 domain to tyrosine
317 of Shc [20]. In addition, Grb2 can utilize SHP-2
as an adapter protein to provide an alternate mech-
anism of MAPK stimulation, or bind directly to
the receptor itself. The clear dissection of the role
played by Grb2 in these alternate complexes in me-
diating G-CSF responses remains an important area
for study.
To further investigate G-CSF-R-mediated signal
transduction in NFS-60 cells, we also sought to ex-
amine whether other cellular proteins might interact
with the G-CSF-R. Therefore, we immunoprecipi-
tated the G-CSF-R from 35P-labelled lysates from
NFS-60 cells, before or after stimulation with G-
CSF. Analysis of the bound cellular proteins by
SDS-PAGE and autoradiography revealed a p37
molecule constitutively-associated with the receptor,
and a p40 molecule associated transiently with the
receptor with a consistent peak at 5 min (Fig. 5A).
To explore these interactions further, we also used
the GST^G-CSF-R fusion protein as an a⁄nity tag
on similarly-labeled lysates to examine those mole-
cules which are capable of directly binding to the
receptor (Fig. 5B). The p37 was not observed, indi-
cating that it either binds indirectly, or interacts with
the extracellular domain of the receptor. However,
this analysis again revealed a p40 molecule which
bound transiently and directly with the G-CSF-R.
In this case, the peak binding was consistently ob-
served 2 min after stimulation, suggesting this mole-
cule may dock ¢rst to the receptor directly, then to
another component present in the G-CSF-R com-
plex. This p40 molecule, therefore, represents an in-
teresting candidate for puri¢cation and microse-
quence analysis, as a ¢rst step in determining its
role in signaling via the G-CSF-R in these cells.
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